-
-
-
-
-
-
News
-
-
Contact UsThe company focuses on the research, development, production, and sales of chemical raw materials and their formulations. All products have passed national GMP certification, and core products have successively passed official pharmaceutical regulatory certifications from multiple countries, including the EU EDQM, US FDA, Japanese PMDA, and South Korean MFDS. Following its successful listing on the Shenzhen Stock Exchange's ChiNext board on April 4, 2023, Keyuan Pharmaceutical has entered a phase of rapid development driven by both digital intelligence and capital, with its business spanning dozens of countries and regions worldwide.
Weikang Bio visited Keyuan Pharmaceutical to jointly explore new pathways for pharmaceutical R&D!
Publish Time:
2026-02-02
On February 2, Professor Liu Pingsheng, founder and chairman of Weikang Shengsheng (Beijing) Biotechnology Co., Ltd. (hereinafter referred to as “Weikang Bio”), along with CEO Dr. Zhang Meng and other core team members, paid a visit to Keyuan Pharmaceutical (stock code: 301281.SZ) for an in-depth discussion. Also attending the meeting were Li Hongfu, Chairman of Keyuan Pharmaceutical; Gao Yuankun, Director; and Gao Chunpo, President.
On February 2, Professor Liu Pingsheng, founder and chairman of Weikang Shengsheng (Beijing) Biotechnology Co., Ltd. (hereinafter referred to as “Weikang Bio”), along with CEO Dr. Zhang Meng and other core team members, paid a visit to Keyuan Pharmaceutical (stock code: 301281.SZ) for an in-depth discussion. Also attending the meeting were Li Hongfu, Chairman of Keyuan Pharmaceutical; Gao Yuankun, Director; and Gao Chunpo, President.
Founded in 2021, Weikang Bio specializes in technological innovation in drug delivery. Its founder and Chairman, Professor Liu Pingsheng, holds multiple prestigious positions, including Distinguished Research Fellow at the Chinese Academy of Sciences, Chief Professor at the University of the Chinese Academy of Sciences, and Secretary-General of the Chinese Biophysical Society. For decades, he has been deeply engaged in the field of lipid droplet biology, amassing profound academic expertise and wielding significant influence within the industry. The company’s core technology—the Adiposome Drug Delivery System (ADDS)—is a groundbreaking, globally pioneering drug-delivery platform that originated from a technology-transfer project incubated by the Institute of Biophysics, Chinese Academy of Sciences. Leveraging biomimicry principles and cutting-edge nanotechnology, ADDS is perfectly tailored for the precise delivery of small-molecule innovative drugs, large-molecule therapeutics such as antibodies, peptides, and nucleic acids, as well as tumor vaccines. Moreover, this technology can be extended to broader health sectors, including nutritional supplements, health care, and beauty & skincare. With its irreplicable technological barriers and versatile application potential across all scenarios, ADDS has become a benchmark innovator in the industry.
The Weikang Bio team comprehensively shared its strategic vision and technology translation plans in the field of pharmaceutical innovation. Both sides engaged in in-depth discussions on key topics including collaborative R&D of innovative drug pipelines, sharing of technical laboratory resources, future development directions in the pharmaceutical sector, and joint deployment in cutting-edge emerging fields. They reached a strategic consensus on jointly exploring frontier markets and co-building an innovative pharmaceutical ecosystem.
This meeting has established an efficient bridge for deepened collaboration between research institutions and pharmaceutical companies. Moving forward, both sides will leverage their respective technological barriers and resource advantages to jointly forge a new path for high-quality development in the pharmaceutical R&D field.
Latest News
Address: No. 26, Keyuan Street, Shanghe County, Jinan City, Shandong Province
Free Service Hotline